This is a preview of subscription content, log in via an institution to check access.
References
Barosi G, Viarengo G, Pecci A et al (2001) Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia. Blood 98(12):3249–3255
Andréasson B, Swolin B, Kutti J (2002) Patients with idiopathic myelofibrosis show increased CD34+ cell concentrations in peripheral blood compared to patients with polycythaemia vera and essential thrombocythaemia. Eur J Haematol 68(4):189–193
Passamonti F, Vanelli L, Malabarba L et al (2003) Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders. Haematologica 88(10):1123–1129
Arora B, Sirhan S, Hoyer JD, Mesa RA, Tefferi A (2005) Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: a prospective evaluation of prognostic value in 94 patients. Br J Haematol 128(1):42–48
Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391–2405
Orvain C, Luque Paz D, Dobo I et al (2016) Circulating Cd34+ cell count differentiates primary myelofibrosis from other Philadelphia-negative myeloproliferative neoplasms: a pragmatic study. Ann Hematol 95(11):1819–1823
Thiele J, Kvasnicka HM, Boeltken B, Zankovich R, Diehl V, Fischer R (1999) Initial (prefibrotic) stages of idiopathic (primary) myelofibrosis (IMF) - a clinicopathological study. Leukemia 13(11):1741–1748
Guglielmelli P, Pacilli A, Rotunno G et al (2017) Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. Blood 129(24):3227–3236
Barbui T, Thiele J, Passamonti F et al (2011) Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol 29(23):3179–3184
Thiele J, Kvasnicka HM, Müllauer L, Buxhofer-Ausch V, Gisslinger B, Gisslinger H (2011) Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. Blood 117(21):5710–5718
Barosi G, Rosti V, Bonetti E et al (2012) Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis. PLoS One 7(4):e35631
Brousseau M, Parot-Schinkel E, Moles MP, Boyer F, Hunault M, Rousselet MC (2010) Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis. Histopathology 56(6):758–767
Gisslinger H (2017) Pre-PMF emerging as important subgroup of MPN. Blood 129(24):3142–3144
Jeryczynski G, Thiele J, Gisslinger B et al (2017) Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: the impact of minor clinical diagnostic criteria on the outcome of the disease. Am J Hematol. 92(9):885–891
Gisslinger H, Jeryczynski G, Gisslinger B et al (2016) Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria. Leukemia 30(5):1126–1132
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Luque Paz, D., Cottin, L., Lippert, E. et al. Different number of circulating CD34 + cells in essential thrombocythemia, prefibrotic/early primary myelofibrosis, and overt primary myelofibrosis. Ann Hematol 101, 893–896 (2022). https://doi.org/10.1007/s00277-021-04672-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-021-04672-z